Paclitaxel binds and activates C5aR1: A new potential therapeutic target for the prevention of chemotherapy-induced peripheral neuropathy and hypersensitivity reactions

Chemotherapy-induced peripheral neuropathy (CIPN) and hypersensitivity reactions (HSRs) are among the most frequent and impairing side effects of the antineoplastic agent paclitaxel. Here, we demonstrated that paclitaxel can bind and activate complement component 5a receptor 1 (C5aR1) and that this...

Descripción completa

Detalles Bibliográficos
Autores principales: Brandolini, Laura, d’Angelo, Michele, Novelli, Rubina, Castelli, Vanessa, Giorgio, Cristina, Sirico, Anna, Cocchiaro, Pasquale, D’Egidio, Francesco, Benedetti, Elisabetta, Cristiano, Claudia, Bugatti, Antonella, Ruocco, Anna, Amendola, Pier Giorgio, Talarico, Carmine, Manelfi, Candida, Iaconis, Daniela, Beccari, Andrea, Quadros, Andreza U., Cunha, Thiago M., Caruso, Arnaldo, Russo, Roberto, Cimini, Annamaria, Aramini, Andrea, Allegretti, Marcello
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9130998/
https://www.ncbi.nlm.nih.gov/pubmed/35614037
http://dx.doi.org/10.1038/s41419-022-04964-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9130998/
https://www.ncbi.nlm.nih.gov/pubmed/35614037
http://dx.doi.org/10.1038/s41419-022-04964-w

Ejemplares similares